GILD Gilead Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GILD

Price (delayed)

$78.74

Market cap

$98.2B

P/E Ratio

21.51

Dividend/share

$2.92

EPS

$3.66

Enterprise value

$118.02B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
GILD's gross profit is up by 7% QoQ and by 4.4% YoY
The gross margin has grown by 6% from the previous quarter and by 4.6% YoY
GILD's P/E is 68% below its 5-year quarterly average of 66.9 but 3.7% above its last 4 quarters average of 20.5
The company's net income rose by 38% QoQ but it fell by 26% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.gilead.com/
Peers: AMGN VRTX ABBV BIIB

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$98.2B
Enterprise value
$118.02B
Valuations
Price to earnings (P/E)
21.51
Price to book (P/B)
4.65
Price to sales (P/S)
3.62
EV/EBIT
17.42
EV/EBITDA
13.29
EV/Sales
4.33
Earnings
Revenue
$27.28B
EBIT
$6.78B
EBITDA
$8.88B
Free cash flow
$8.34B
Per share
EPS
$3.66
Free cash flow per share
$6.65
Book value per share
$16.93
Revenue per share
$21.74
TBVPS
$20.69
Balance sheet
Total assets
$63.17B
Total liabilities
$41.96B
Debt
$25.23B
Equity
$21.24B
Working capital
$3.21B
Liquidity
Debt to equity
1.19
Current ratio
1.29
Quick ratio
0.99
Net debt/EBITDA
2.23
Margins
EBITDA margin
32.5%
Gross margin
79.3%
Net margin
16.8%
Operating margin
26.9%
Efficiency
Return on assets
7.3%
Return on equity
22.3%
Return on invested capital
18.8%
Return on capital employed
13%
Return on sales
24.8%
Dividend
Dividend yield
3.71%
DPS
$2.92
Payout ratio
79.8%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
1.2%
1 week
-1.39%
1 month
-4.6%
1 year
33.8%
YTD
-8.28%
QTD
-8.28%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$27.28B
Gross profit
$21.62B
Operating income
$7.33B
Net income
$4.59B
Gross margin
79.3%
Net margin
16.8%
The company's net income rose by 38% QoQ but it fell by 26% YoY
Gilead Sciences's net margin has increased by 37% QoQ but it has decreased by 26% YoY
The operating margin has contracted by 26% YoY but it has grown by 22% from the previous quarter
The operating income has declined by 26% year-on-year but it has grown by 22% since the previous quarter

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
21.51
P/B
4.65
P/S
3.62
EV/EBIT
17.42
EV/EBITDA
13.29
EV/Sales
4.33
GILD's P/E is 68% below its 5-year quarterly average of 66.9 but 3.7% above its last 4 quarters average of 20.5
GILD's EPS is up by 37% since the previous quarter but it is down by 26% year-on-year
The stock's price to book (P/B) is 12% more than its last 4 quarters average of 4.1 and 9% more than its 5-year quarterly average of 4.2
GILD's price to sales (P/S) is 15% more than its last 4 quarters average of 3.1

Efficiency

How efficient is Gilead Sciences business performance
GILD's return on assets is up by 40% since the previous quarter but it is down by 21% year-on-year
The company's return on equity rose by 38% QoQ but it fell by 27% YoY
GILD's return on sales is down by 27% year-on-year but it is up by 22% since the previous quarter
Gilead Sciences's ROIC has increased by 24% from the previous quarter but it has decreased by 22% YoY

Dividends

What is GILD's dividend history
Dividend details
DPS
$2.92
Dividend yield
3.71%
Payout ratio
79.8%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 51% higher than its total liabilities
The total liabilities has contracted by 11% YoY
GILD's total assets is down by 7% YoY
Gilead Sciences's debt is 19% higher than its equity
The company's debt to equity fell by 6% YoY
Gilead Sciences's debt has decreased by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.